Special Issue "Immune Responses in Coronavirus Disease"

A special issue of COVID (ISSN 2673-8112).

Deadline for manuscript submissions: 31 October 2023 | Viewed by 261

Special Issue Editor

1. Blood Transfusion and Donor Services, Maimonides Medical Center, Brooklyn, NY, USA
2. Department of Pathology, Wayne State University School of Medicine, Detroit, MI, USA
Interests: biomarker discovery; inflammation; immunotherapeutics; IgE/IgG antibody regulation; ADCC
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

COVID-19 has both devastated and revolutionized the way we address pandemic-based health and disease. We have matured from nucleic-acid-based testing, social distancing, personal protective equipment, and stay-at-home mandates to immunization, treatment modalities with side-effect profiling, rapid antigen testing, variation/mutation in COVID-19 infection as well as severity of symptom presentation. While it appears that the worst of the COVID-19 pandemic may be behind us, the question of the state of our functional immune status post-natural infection and/or vaccination remains an area of importance. Initial assessment of anti-COVID-19 immunity status gave rise to various treatment modalities, including COVID-19 Convelescent Plasma, hyper-COVID-19 immunoglobulin preparations, select cellular therapies, and immunization regiments to name a few. What about going forward? How do we know if we have a modicum of functional immunity to combat the current or potential new versions of COVID-19? This includes general anti-COVID-19 immunoglobulin presence, neutralizing antibodies, cellular-based responses and the like. This Special Issue on "Immune Responses in Coronavirus Disease" seeks to explore this important question in greater detail. The relationships of immunoglobulin isotypes and subclasses, dendridic cell activation, and everything in between that can induce functional protective immunity by way of opsonization, neutralization, eradication, as well as minimization of previous, current, and potentially future COVID-19 insults remains the subject matter of this Special Issue. COVID is likely here to stay. Understanding how we immunologically relate to the vestiges of this pandemic will help us navigate how we will interact with it in the days to come.

Prof. Dr. Martin H. Bluth
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. COVID is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • COVID-19
  • Coronavirus
  • immune response
  • neutralizing antibody
  • convelescent plasma

Published Papers

This special issue is now open for submission.
Back to TopTop